Lung cancer screening in Australia and New Zealand: the evidence and the challenge.
Australia
New Zealand
low-dose CT
lung cancer
screening
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
21
07
2020
accepted:
23
08
2020
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
1
6
2021
Statut:
ppublish
Résumé
Lung cancer remains the commonest cause of cancer death in Australia and New Zealand. Targeted screening of individuals at highest risk of lung cancer aims to detect early stage disease, which may be amenable to potentially curative treatment. While current policy recommendations in Australia and New Zealand have acknowledged the efficacy of lung cancer screening in clinical trials, there has been no implementation of national programmes. With the recent release of findings from large international trials, the evidence and experience in lung cancer screening has broadened. This article discusses the latest evidence and implications for Australia and New Zealand.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
436-441Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2019. Canberra: AIHW; 2019; 174.
Australian Government Department of Health's Standing Committee on Screening. Position Statement: Lung Cancer Screening Using Low-Dose Computed Tomography 2015. Canberra: Australian Department of Health; 2015: 6 [cited 2020 Jul 18]. Available from URL: www.cancerscreening.gov.au
Jaine R, Kvizhinadze G, Nair N, Blakely T. Cost-effectiveness of a low-dose computed tomography screening program for lung cancer in New Zealand. Lung Cancer 2020; 144: 99-106.
The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
Moyer VA. Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2014; 160: 330-8.
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020; 382: 503-13.
Huang KL, Wang SY, Lu WC, Chang YH, Su J, Lu YT. Effects of low-dose computed tomography on lung cancer screening: a systematic review, meta-analysis, and trial sequential analysis. BMC Pulm Med 2019; 19: 126.
Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014; 174: 269-74.
Frank L, Christodoulou E, Kazerooni EA. Radiation risk of lung cancer screening. Semin Respir Crit Care Med 2013; 34: 738-47.
Rampinelli C, De Marco P, Origgi D, Maisonneuve P, Casiraghi M, Veronesi G et al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. BMJ 2017; 356: j347.
Crosbie PA, Balata H, Evison M, Atack M, Bayliss-Brideaux V, Colligan D et al. Implementing lung cancer screening: baseline results from a community-based ‘Lung Health Check’ pilot in deprived areas of Manchester. Thorax 2019; 74: 405-9.
Ministry of Health. Tatau Kahukura: Māori Health Chart Book, 3rd edn. Wellington: The Ministry; 2015.
Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ et al. Screening for lung cancer. Cochrane Database Syst Rev 2013; CD001991.
Marshall HM, Bowman RV, Ayres J, Crossin J, Lau M, Slaughter RE et al. Lung cancer screening feasibility in Australia. Eur Resp J 2015; 45: 1734-7.
Lim KP, Marshall H, Tammemägi M, Brims F, McWilliams A, Stone E et al. Protocol and rationale for the international lung screen trial. Ann Am Thorac Soc 2020; 17: 503-12.
Australian Bureau of Statistics (ABS). 2016 Census QuickStats. Canberra: ABS; 2017 [cited 2020 Jul 18]. Available from URL: www.abs.gov.au
Australian Institute of Health and Welfare (AIHW). National Cancer Screening Programs Participation Data. CAN 114. Canberra: AIHW; 2020 [cited 2020 Jul 18]. Available from URL: www.aihw.gov.au
Stats NZ. Wellington: Stats NZ; 2014 [cited 2020 Jul 18]. Available from URL: http://archive.stats.govt.nz/Census/2013-census/profile-and-summary-reports/quickstats-culture-identity/ethnic-groups-NZ.aspx
Ministry of Health. BreastScreen Aotearoa Coverage: New Zealand - March 2020. Wellington: The Ministry; 2020 [cited 2020 Jul 18]. Available from URL: https://www.nsu.govt.nz/health-professionals/breastscreen-aotearoa/breast-screening-dhb-quarterly-reports/march-2020
Ministry of Health. Bowel Screening Pilot Monitoring Indicators. Wellington: The Ministry; 2018 [cited 2020 Jul 18]. Available from URL: https://www.health.govt.nz/our-work/preventative-health-wellness/screening/bowel-screening-pilot/bowel-screening-pilot-monitoring-indicators
Chan JCY, Gupta A, Stewart SK, McCulloch GAJ, Babidge WJ, Worthington MG et al. Mortality in Australian cardiothoracic surgery: findings from a national audit. Ann Thorac Surg 2020; 109: 1880-8.
Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE et al. UK lung cancer RCT pilot screening trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 2016; 71: 161-70.
Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med 2014; 371: 1793-802.
Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One 2013; 8: e71379.
Cressman S, Peacock SJ, Tammemägi MC, Evans WK, Leighl NB, Goffin JR et al. The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency. J Thorac Oncol 2017; 12: 1210-22.
Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer 2005; 48: 171-85.
Wade S, Weber M, Caruana M, Kang YJ, Marshall H, Manser R et al. Estimating the cost-effectiveness of lung cancer screening with low-dose computed tomography for high-risk smokers in Australia. J Thorac Oncol 2018; 13: 1094-105.
Crengle S. Comment on: Jaine et al cost-effectiveness of a low-dose computed tomography screening program for lung cancer in New Zealand. Lung Cancer 2020; 145: 219-20.
U.S. Preventative Services Task Force. Draft Recommendation Statement: Lung Cancer: Screening. Rockville, MD: USPSTF; 2020 [cited 2020 Jul 18]. Available from URL: https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/lung-cancer-screening-2020
Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso NE, Kvale PA et al. Selection criteria for lung-cancer screening. N Engl J Med 2013; 368: 728-36.
Weber M, Yap S, Goldsbury D, Manners D, Tammemägi M, Marshall H et al. Identifying high risk individuals for targeted lung cancer screening: independent validation of the PLCOm2012 risk prediction tool. Int J Cancer 2017; 141: 242-53.
Han SS, Chow E, ten Haaf K, Toumazis I, Cao P, Bastani M et al. Disparities of national lung cancer screening guidelines in the U.S. population. J Natl Cancer Inst 2020; 112: 1136-42.
See K, Manser R, Park ER, Steinfort D, King B, Piccolo F et al. The impact of perceived risk, screening eligibility and worry on preference for lung cancer screening: a cross-sectional survey. ERJ Open Res 2020; 6: 00158-2019.
Standing Committee on Screening. Population Based Screening Framework Updated August 2018. Canberra: Australian Government Department of Health; 2018 [cited 2020 Jul 18]. Available from URL: https://www.cancerscreening.gov.au
National Screening Unit. National Screening Unit Quality Framework 2015: Delivering Screening Programs. Wellington: Ministry of Health; 2015 [cited 2020 Jul 18]. Available from URL: https://www.nsu.govt.nz/about-us-national-screening-unit/quality-improvement
Manners D, Hui J, Hunter M, James A, Knuiman MW, McWilliams A et al. Estimating eligibility for lung cancer screening in an Australian cohort, including the effect of spirometry. Med J Aust 2016; 204: 406.
Emery JD, Shaw K, Williams B, Mazza D, Fallon-Ferguson J, Varlow M et al. The role of primary care in early detection and follow-up of cancer. Nat Rev Clin Oncol 2014; 11: 38-48.
Abeyweera PD, Brims FJH, Piccolo F, Lei C, Manners D. Australia-wide cross-sectional survey of general practitioners’ knowledge and practice of lung cancer screening. Intern Med J 2020. doi:10.1111/imj.14838.
Headrick JR Jr, Morin O, Miller AD, Hill L, Smith J. Mobile lung screening: should we all get on the bus? Ann Thorac Surg 2020; 110: 1147-52.
Ganeshan D, Rosenkrantz AB, Bassett RL Jr, Williams L, Lenchik L, Yang W. Burnout in academic radiologists in the United States. Acad Radiol 2020; 27: 1274-81.
Cancer Council. Optimal Care Pathway for People with Lung Cancer. Sydney: Cancer Council; 2016 [cited 2020 Jul 18]. Available from URL: http://www.cancer.org.au/ocp
Stevens W, Stevens G, Kolbe J, Cox B. Ethnic differences in the management of lung cancer in New Zealand. J Thorac Oncol 2008; 3: 237-44.
Centers for Medicare & Medicaid Services. Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT). Baltimore, MD: Centers for Medicare & Medicaid Services; 2015 [cited 2020 Jul 18]. Available from URL: http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274
Manners D, Pettigrew S, Lake FR, Piccolo F, McWilliams AM, Brims FJH. Development and evaluation of a consumer information resource, including Patient Decision Aid, for lung cancer screening: a quasi-experimental study. Transl Behav Med 2020; 10: 404-12.
Rasmussen JF, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST). Lung Cancer 2015; 87: 65-72.